Navigation Links
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Date:7/15/2009

MADISON, Wis., July 15 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that it has exclusively in-licensed a US-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells (cardiomyocytes) in drug testing.

The license, obtained from Dr. Loren Field and Indiana University-Purdue University Indianapolis (IUPUI), covers two important concepts for using stem cell-derived cells for drug screening. First, the Field patents cover a cell purification strategy that enables greater than 90 percent purity of any type of cells. Secondly, the Field patents cover the use of stem cell-derived cardiomyocytes for drug testing. Financial terms of the license were not disclosed.

"CDI is building an industrial pipeline and automated process enabling us to plug in different cell types and generate large quantities of purified cells," said Chris Kendrick-Parker, chief commercial officer of CDI. "That is the primary requirement for commercial application of these cells as tools in the pharmacology and toxicity testing market. Similar to our recently announced in-licensed patent portfolio from Mount Sinai School of Medicine, the IUPUI agreement ensures that we have a commercial advantage in this area, providing our customers with the comfort that they are unencumbered when they do business with us."

Brad Fravel, business development manager at Indiana University Research & Technology Corporation said, "As a leader in the pluripotent stem cell field, CDI is a great licensing partner for IUPUI. We are confident CDI will run with this technology, exploiting it to its fullest potential."

The license enables CDI to optimize the process of developing and purifying different cell types created from human pluripotent stem cells, including the company's first commercially available product line, human cardiomyocytes. Under the licensed technology, pluripotent stem cells are engineered to include a selectable "marker." As the stem cells begin to differentiate into different terminal cell types (e.g. heart, blood, neural cells, etc.), the marker allows researchers to identify and select a particular cell type (e.g. heart cells) and produce a highly purified and functional cell population.

The license also covers the use of cardiomyocytes purified through this technology for drug testing. While cardiomyocytes are the company's entree into the market, the company has programs in place for developing multiple cell types, and the Field patents enable the company to develop them into highly purified populations. CDI is using the Field technology in conjunction with the patents it has licensed from the Wisconsin Alumni Research Foundation (WARF), UW-Madison's tech-transfer vehicle, to create a pipeline that mass produces cells for large-scale drug screening campaigns at pharmaceutical companies and for regenerative medicine applications.

In addition the license, which includes patents pending at the European Patent Office, also allows CDI to sublicense to other companies and institutions.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPS technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based venture capital fund. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.

    MEDIA CONTACTS:
    Joleen Rau
    Senior Director, Marketing & Communications
    Cellular Dynamics International, Inc.
    (608) 310-5142
    jrau@cellulardynamics.com

    Robert E. Flamm, Ph.D.
    Russo Partners LLC
    robert.flamm@russopartnersllc.com
    (212) 845-4226

    Tony Russo
    Russo Partners LLC
    tony.russo@russopartnersllc.com
    (212) 845-4251


'/>"/>
SOURCE Cellular Dynamics International (CDI)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
2. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
3. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
4. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
5. MIT, BU engineer cellular circuits that count events
6. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
7. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
8. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
9. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
10. Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
11. New insights into cellular reprogramming revealed by genomic analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, Slone ... Search Firm by Hunt Scanlon Media. , Hunt Scanlon Media is one ... widely referenced global news source in the human capital sector. , “It is a ...
(Date:3/22/2017)... ... 21, 2017 , ... The Conference Forum has announced the launch of the ... May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO Summit is ... learning, benchmarking and support. , “The Chief Medical Officer faces a unique set of ...
Breaking Biology Technology:
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
Breaking Biology News(10 mins):